Close Menu
Global News HQ
    What's Hot

    Etro Spring 2026 Menswear Collection

    June 24, 2025

    Cigna Sued for Allegedly Sharing Medical Data With Third-Party Advertisers | Law.com

    June 24, 2025

    A Shopper’s Thin Hair Has ‘More Body and Bounce’ Than It’s Had In ‘Years’ With This $6 Thickening Shampoo

    June 24, 2025
    Recent Posts
    • Etro Spring 2026 Menswear Collection
    • Cigna Sued for Allegedly Sharing Medical Data With Third-Party Advertisers | Law.com
    • A Shopper’s Thin Hair Has ‘More Body and Bounce’ Than It’s Had In ‘Years’ With This $6 Thickening Shampoo
    • How to Clean a Dryer Vent Yourself
    • Chase credit cards: Best time to apply based on offer history – The Points Guy
    Facebook X (Twitter) Instagram YouTube TikTok
    Trending
    • Etro Spring 2026 Menswear Collection
    • Cigna Sued for Allegedly Sharing Medical Data With Third-Party Advertisers | Law.com
    • A Shopper’s Thin Hair Has ‘More Body and Bounce’ Than It’s Had In ‘Years’ With This $6 Thickening Shampoo
    • How to Clean a Dryer Vent Yourself
    • Chase credit cards: Best time to apply based on offer history – The Points Guy
    • Microsoft’s Xbox UI update lets you pin games and customize your homescreen
    • Alibaba and SAP expand cloud AI with implications for B2B ecommerce
    • I Predict This “Magnificent Seven” Stock Will Crush Expectations | The Motley Fool
    Global News HQ
    • Technology & Gadgets
    • Travel & Tourism (Luxury)
    • Health & Wellness (Specialized)
    • Home Improvement & Remodeling
    • Luxury Goods & Services
    • Home
    • Finance & Investment
    • Insurance
    • Legal
    • Real Estate
    • More
      • Cryptocurrency & Blockchain
      • E-commerce & Retail
      • Business & Entrepreneurship
      • Automotive (Car Deals & Maintenance)
    Global News HQ
    Home - Finance & Investment - Why Summit Therapeutics Plunged Today | The Motley Fool
    Finance & Investment

    Why Summit Therapeutics Plunged Today | The Motley Fool

    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Why Summit Therapeutics Plunged Today | The Motley Fool
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Shares of Summit Therapeutics (SMMT -28.08%) have plunged 31% as of 1:23 p.m. ET Friday, following the release of some trial data this morning.

    Summit has been a tremendous winner over the past year, as its bispecific antibody lung cancer drug ivonescimab outperformed prior standards of care in phase 3 trials performed in China by Summit’s partner Akeso (AKES.F -5.51%).

    While today’s results weren’t all bad by any means, apparently investors had hoped for more conclusive information about survival rates. With such high expectations, it appears investors are taking profits or de-risking in a big way.

    “Mixed” data gets a thumbs-down from investors, but analysts aren’t worried

    Today’s release showed results of the fourth phase 3 trial known as “HARMONi,” the first to include a significant Western patient population (about a third of participants). Last year’s positive results largely came from a China-only study.

    On the positive side, today’s data did show that ivonescimab in combination with chemotherapy reduced the risk of disease progression or death by 48%. In addition, the company noted no significant differences between the Asian and Western patient populations. However, the trial didn’t show a “statistically significant” benefit in overall survival.

    Summit has been hoping to apply for FDA approval for ivonescimab in the U.S., but the FDA has told the company it will need to show that statistically significant survival benefit in order to get it. Investors may be getting nervous about that eventual approval.

    However, analysts don’t believe investors should panic. Jefferies biotech analyst Kelly Shi noted the survival endpoint still has a chance of being reached as the data matures further and Western trial patients continue to show survival benefits. So basically, it doesn’t appear as though the trial has lasted long enough to reach the statistically significant survival threshold, which doesn’t mean that it won’t get there.

    Image source: Getty Images.

    Analysts still encouraged: A buying opportunity?

    Another analyst was also bullish on the data, despite today’s drop. Cantor Fitzgerald biotech analyst Eric Schmidt said, “We think it is fairly clear that this is a drug! … In each of these four trials, the data posted by ivonescimab appear differentiated from and superior to PD-1 therapy.”

    Therefore, investors may want to take a look at Summit on this drop. While today’s data didn’t meet the threshold many investors had been hoping for, there is still a chance that it will with more time. Given the success ivonescimab has demonstrated over the past year, it seems likely, though not certain, the drug will eventually be approved.

    Of course, it’s a bit difficult to value a stock like Summit, which has a promising drug candidate but no real current revenues and a market cap that, even down 30% today, is still over $13.5 billion.

    Billy Duberstein and/or his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Jefferies Financial Group and Summit Therapeutics. The Motley Fool has a disclosure policy.

    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleUBS, Dior announce joint ‘House of Craft’ exhibit
    Next Article What Is a Mother-in-Law Suite, and Does It Add Property Value?

    Related Posts

    I Predict This “Magnificent Seven” Stock Will Crush Expectations | The Motley Fool

    June 23, 2025

    Military briefing: will Iran start a new ‘tanker war’?

    June 23, 2025

    Chop Tape Sets The Market Up For Higher (Technical Analysis) (NASDAQ:QQQ)

    June 23, 2025

    The Best Stocks to Invest $50,000 in Right Now | The Motley Fool

    June 23, 2025
    Leave A Reply Cancel Reply

    ads
    Don't Miss
    Luxury Goods & Services
    1 Min Read

    Etro Spring 2026 Menswear Collection

    Etro took a quieter route this season, presenting its men’s collection without fanfare in a…

    Cigna Sued for Allegedly Sharing Medical Data With Third-Party Advertisers | Law.com

    June 24, 2025

    A Shopper’s Thin Hair Has ‘More Body and Bounce’ Than It’s Had In ‘Years’ With This $6 Thickening Shampoo

    June 24, 2025

    How to Clean a Dryer Vent Yourself

    June 24, 2025
    Top
    Luxury Goods & Services
    1 Min Read

    Etro Spring 2026 Menswear Collection

    Etro took a quieter route this season, presenting its men’s collection without fanfare in a…

    Cigna Sued for Allegedly Sharing Medical Data With Third-Party Advertisers | Law.com

    June 24, 2025

    A Shopper’s Thin Hair Has ‘More Body and Bounce’ Than It’s Had In ‘Years’ With This $6 Thickening Shampoo

    June 24, 2025
    Our Picks
    Luxury Goods & Services
    1 Min Read

    Etro Spring 2026 Menswear Collection

    Etro took a quieter route this season, presenting its men’s collection without fanfare in a…

    Legal
    1 Min Read

    Cigna Sued for Allegedly Sharing Medical Data With Third-Party Advertisers | Law.com

    The industry-leading media platform offering competitive intelligence to prepare for today and anticipate opportunities for…

    Pages
    • About Us
    • Contact Us
    • Disclaimer
    • Homepage
    • Privacy Policy
    Facebook X (Twitter) Instagram YouTube TikTok
    • Home
    © 2025 Global News HQ .

    Type above and press Enter to search. Press Esc to cancel.

    Go to mobile version